Senior Vice President and Chief Medical Officer · ImmunoGen, Inc. (IMGN)

Anna Berkenblit

A named executive officer of ImmunoGen in every fiscal year CompBrief holds from FY2020 to FY2022. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2022

$1,889,484

Salary $512,302

FY2021: $2,510,490

3rd of 6 named executive officers at ImmunoGen by FY2022 total.

6 named officers on file for ImmunoGen, FY2022

Anna Berkenblit’s pay file — $29

  • 3 fiscal years of pay, line by line
  • 1 equity grant, each cited to its filing
  • IMGN’s disclosed peer group of 21 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how ImmunoGen’s whole pay program stands against its peers

  • ImmunoGen’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on IMGN→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 26, 2023 (DEF 14A).

Free

Get Anna Berkenblit’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Anna Berkenblit compensation by year

ImmunoGen Summary Compensation Table · all 3 fiscal years held
In US dollars, as ImmunoGen reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020FY2021FY2022
Salary$480,233$496,237$512,302
Option awards$958,326$1,863,213$1,172,444
Non-equity incentive$152,131$141,368$194,616
All other$9,372$9,672$10,122
Total$1,600,062$2,510,490$1,889,484

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: ImmunoGen, Inc. DEF 14A filed April 26, 2023, accession 0001558370-23-006874, and prior-year filings. Open the filing on EDGAR.

How this page was built: the ImmunoGen, Inc. filed document, accession 0001558370-23-006874. Every figure is read from that document and cited to the page and table it appears in. Filed April 26, 2023.

$1.6M
$2.5M
$1.9M
FY20
FY21
FY22
SalaryNon-equity incentiveOption awardsAll other

Equity holdings

unvested awards at FY2022 year-end
TypeUnvested unitsValue at year-endExercise price
Option23,125—$5.25
Option92,625—$4.55
Option55,575—$4.55
Option311,700—$5.32
Option158,635—$7.69

Per the Outstanding Equity Awards at Fiscal Year-End table in ImmunoGen, Inc.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.

Change-in-control & termination

estimated payments ImmunoGen discloses, by trigger · FY2022
TriggerCash severanceAccelerated equityBenefits continuationTotal as disclosed
Involuntary termination without cause$514,857—$39,399$760,199
Change in control and involuntary termination$1,081,200$60,762$59,099$1,241,061

Per the Potential Payments Upon Termination or Change in Control table in ImmunoGen, Inc.'s FY2022 proxy. Estimates as the company printed them; a dash means it printed no figure.

ImmunoGen’s named executive officers, FY2022

as the company reported each
Named executive officerRoleFY2022 total
Mark EnyedyPresident and Chief Executive Officer$5,422,421
Michael VasconcellesExecutive Vice President Research, Development and Medical Affairs$3,814,652
Anna Berkenblit · this pageSenior Vice President and Chief Medical Officer$1,889,484
Stacy CoenSenior Vice President and Chief Business Officer$1,838,354
Susan AltschullerFormer Senior Vice President and Chief Financial Officer$1,791,733
Renee LentiniVice President and Interim Chief Financial Officer$965,989

The full ImmunoGen compensation record

free company brief

This page is one person within ImmunoGen's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the ImmunoGen proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are ImmunoGen's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Anna Berkenblit's compensation dossier · One-time report. No refunds.